Heartflow, Inc. (NASDAQ:HTFL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Heartflow, Inc. (NASDAQ:HTFL) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $38.50.

A number of research firms have commented on HTFL. Stifel Nicolaus raised their price target on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Canaccord Genuity Group raised their target price on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wells Fargo & Company began coverage on Heartflow in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 target price for the company. JPMorgan Chase & Co. increased their price target on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th.

Insider Buying and Selling at Heartflow

In related news, Director Julie A. Cullivan sold 8,000 shares of the firm’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $27.32, for a total value of $218,560.00. Following the transaction, the director owned 36,413 shares of the company’s stock, valued at approximately $994,803.16. This trade represents a 18.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00. Following the transaction, the insider directly owned 10,448,158 shares in the company, valued at approximately $293,070,831.90. The trade was a 16.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,095,715 shares of company stock worth $58,533,709 in the last ninety days.

Hedge Funds Weigh In On Heartflow

A number of hedge funds and other institutional investors have recently modified their holdings of HTFL. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow in the fourth quarter valued at about $27,000. TFC Financial Management Inc. bought a new position in Heartflow during the third quarter valued at $40,000. Russell Investments Group Ltd. bought a new position in Heartflow during the fourth quarter valued at $45,000. Legal & General Group Plc purchased a new stake in Heartflow in the third quarter worth $59,000. Finally, Strs Ohio bought a new stake in shares of Heartflow in the fourth quarter valued at $99,000.

Heartflow Stock Down 3.9%

NASDAQ:HTFL opened at $23.16 on Tuesday. Heartflow has a twelve month low of $20.13 and a twelve month high of $41.22. The company has a fifty day moving average of $29.09 and a 200-day moving average of $31.22. The firm has a market capitalization of $1.97 billion and a P/E ratio of -12.80.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.